Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
204
datasets available to search
ShareScore release 0.9.0
Dataset results
204 results for “chronic migraine”
Study of Quality of Life in Subjects With Chronic or High-frequency Episodic Migraine and Associated Comorbidities Treated With Erenumab
ClinicalTrials.gov study NCT04114630. IPD Sharing: YES. Countries: 1. Publications: 0.
Brief Interventions in Chronic Migraine
ClinicalTrials.gov study NCT05979337. IPD Sharing: YES. Countries: 1. Publications: 0.
Flunarizine Versus Topiramate for Chronic Migraine Prophylaxis
ClinicalTrials.gov study NCT02639598. IPD Sharing: NO. Countries: 0. Publications: 12.
A Retrospective Chart Review to Evaluate Diagnosis and Treatment of Chronic Migraine and Headache
ClinicalTrials.gov study NCT01946126. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Retrospective Study to Evaluate the Effectiveness and Benefit of onabotulinumtoxinA in Patients With Chronic Migraines
ClinicalTrials.gov study NCT01749410. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Efficacy of Nerve Block Versus Botox in Chronic Migraine Management
ClinicalTrials.gov study NCT06684249. IPD Sharing: NO. Countries: 1. Publications: 0.
Evaluation of the Effectiveness of Topiramate in Preventing the Transformation From Episodic Migraine to Chronic Daily Headache.
ClinicalTrials.gov study NCT00212810. IPD Sharing: Not stated. Countries: 0. Publications: 1.
Data from: Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study
Open the record for dataset details and reuse information.
Supplemental material for: PROMISE-2: Efficacy and safety of eptinezumab in patients with chronic migraine
Objective: To evaluate the efficacy and safety of eptinezumab, a humanized anti–calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM). Methods: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy–2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive intravenous (IV) eptinezumab 100 mg, eptinezumab 300 mg, or placebo, administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1–12. Results: Among treated participants (n = 1072), baseline mean MMDs was ~16.1 across groups. Treatment with eptinezumab 100 mg and 300 mg was associated with significant reductions in MMDs across weeks 1–12 compared with placebo (placebo, −5.6, 100 mg, −7.7, p < 0.0001 vs placebo; 300 mg, −8.2, p < 0.0001 vs placebo). Treatment-emergent adverse events (TEAEs) were reported by 43.5% (100 mg), 52.0% (300 mg), and 46.7% (placebo) of patients. Nasopharyngitis was the only TEAE reported for >2% of eptinezumab treated patients at an incidence of greater than 2% over placebo; it occurred in the 300 mg eptinezumab arm (eptinezumab 9.4%, placebo 6.0%). Conclusion: In patients with CM, eptinezumab 100 mg and 300 mg was associated with a significant reduction in MMDs from the day following IV administration through week 12, was well tolerated, and demonstrated an acceptable safety profile.
Dataset related to article:MULTIMODAL DIGITAL HEALTH TREATMENTS FOR CHRONIC MIGRAINE ASSOCIATED WITH MEDICATION OVERUSE HEADACHE: A LITERATURE APPRAISAL AND RESULTS OF A SINGLE‑ARM OPEN TRIAL (THE BE‑HOME PROGRAM)
<p><strong><span>Variables related to baseline, months 3, 6 and 12 referred to headache frequency, medication intake, GSE, HIT-6, BDI-II, MSQ and PCS, of patients with CM and MOH who participated to the BE-HOME trial.</span></strong></p>
A Feasibility Clinical Trial to Evaluate High Frequency Spinal Cord Stimulation for the Treatment of Patients With Chronic Migraine
ClinicalTrials.gov study NCT01653340. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Open Label, 6-month Study for High Frequency and Chronic Migraine,
ClinicalTrials.gov study NCT06133491. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine
ClinicalTrials.gov study NCT05164172. IPD Sharing: Not stated. Countries: 11. Publications: 0.
The Effect of Accompanying Temporomandibular Joint Dysfunction in Patients With Chronic Migraine
ClinicalTrials.gov study NCT05381129. IPD Sharing: NO. Countries: 1. Publications: 0.
Repetitive Transcranial Magnetic Stimulation in Treatment and Prophylaxis of Chronic Migraine in Patients With no Prophylactic Treatment for the Last 3 Months
ClinicalTrials.gov study NCT06461767. IPD Sharing: YES. Countries: 1. Publications: 0.
Transcranial Direct Current Stimulation Associated With Mindfulness in Chronic Migraine
ClinicalTrials.gov study NCT04219345. IPD Sharing: NO. Countries: 1. Publications: 0.
Fibromyalgia Syndrome on Patients With Chronic Migraine
ClinicalTrials.gov study NCT05381012. IPD Sharing: NO. Countries: 1. Publications: 0.
The Effect of Interventional Procedures on Serum CGRP and PACAP-38 Levels in Chronic Migraine
ClinicalTrials.gov study NCT07395908. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Treatment of Chronic Migraine With Erenumab Alone or as an Add on Therapy
ClinicalTrials.gov study NCT04152434. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study With Intranasal Kinetic Oscillation Stimulation (KOS) in the Prevention of Chronic Migraine
ClinicalTrials.gov study NCT05273151. IPD Sharing: NO. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.